Drugs / Apixiban
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04168398 | Jul 2019 → Nov 2021 | limb ischemia | Mansoura University | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT02666742 | Feb 2017 → May 2020 | stroke disorder, ventricular tachycardia | Kansas City Heart Rhythm Institute | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT02885545 Comparator | Sep 2016 → Mar 2018 | chronic kidney disease, stroke disorder | Population Health Research Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT04684212 Comparator | Jun 2024 | atrial fibrillation, stroke disorder | Brian O'Neill MD | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apixiban | “vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od” NCT02885545 ↗3“Apixiban 2.5 twice daily (Eliquis 2.5mg) plus Aspirin 81 mg.” NCT04168398 ↗ “Apixiban” NCT02666742 ↗ |
| Known as | Eliquis | “Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)” NCT04684212 ↗1“Apixiban 2.5 twice daily (Eliquis 2.5mg) plus Aspirin 81 mg.” NCT04168398 ↗ |
| Route | Oral | “Market approved oral anticoagulation (OAC)” NCT04684212 ↗ |